{"schema_version":"secwatch.filing_event.v1","accession":"0001398733-26-000035","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2026-08-10T11:05:44+00:00","discovered_at":"2026-08-10T11:10:00.481591+00:00","generated_at":"2026-08-10T11:10:09.512010+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive reports positive Anaphylm human factors and PK study results; NDA resubmission on track for Q3 2026","bullets":["Median pouch-open time cut from 17s to 3s; incorrect film placement down >80% in revised HF study.","PK study: self-admin Cmax 391.7 pg/mL vs clinician 357.6 and IM 334.5; Tmax 12 min vs 45 min for IM.","Top-of-tongue placement still gave Cmax >100 pg/mL and PD comparable to injectable epinephrine.","No serious adverse events or discontinuations in PK study; no administration errors in self-administration arm.","NDA resubmission on track for Q3 2026; also advancing filings in Canada, UK, EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001398733-26-000035","json":"https://secwatch.observer/filing/0001398733-26-000035.json","markdown":"https://secwatch.observer/filing/0001398733-26-000035.md","text":"https://secwatch.observer/filing/0001398733-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/0001398733-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000035/aqst-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:10:09.512010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}